Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders

Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders

Agomelatine (AGM) is one of the latest atypical antidepressants, prescribed exclusively for the treatment of depression in adults. AGM belongs to the pharmaceutical class of melatonin agonist and selective serotonin antagonist (“MASS”), as it acts both as a selective agonist of melatonin receptors M...

Full description

Bibliographic Details
Main Authors: Rosa Savino, Anna Nunzia Polito, Gabriella Marsala, Antonio Ventriglio, Melanie Di Salvatore, Maria Ida De Stefano, Anna Valenzano, Luigi Marinaccio, Antonello Bellomo, Giuseppe Cibelli, Marcellino Monda, Vincenzo Monda, Antonietta Messina, Rita Polito, Marco Carotenuto, Giovanni Messina
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Brain Sciences
Subjects:
AGM
melatonin agonist and selective serotonin antagonist (MASS)
autism spectrum disorder (ASD)
attention deficit hyperactivity disorder (ADHD)
neurodevelopmental disorders
Online Access:https://www.mdpi.com/2076-3425/13/5/734

Internet

https://www.mdpi.com/2076-3425/13/5/734

Similar Items